AstraZeneca’s Farxiga Fast Track’d for heart failure following heart attack

The FDA has granted Fast Track status to AstraZeneca’s (NYSE:AZN) Farxiga (dapagliflozin) to reduce the risk of hospitalization for heart failure or cardiovascular (CV) death in adults following an acute myocardial infarction (heart attack).

Fast Track provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.

https://seekingalpha.com/news/3591807-astrazenecas-farxiga-fast-trackd-for-heart-failure-following-heart-attack